CoChat

Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study

Bomgaars, Lisa R., Bernstein, Mark, Krailo, Mark, Kadota, Richard, Das, Soma, Chen, Zhengjia, Adamson, Peter C., Blaney, Susan M. · 2007 · Journal of Clinical Oncology
Cited by 141

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Purpose: A phase II study was performed to determine the efficacy of irinotecan (IRN) in children with refractory solid tumors. Secondary objectives were to evaluate toxicity, pharmacokinetics, pharmacodynamics, and UGT1A1 genotype. Patients and Methods: A total of 181 patients were enrolled, of whom 171 were eligible. Patients received IRN 50 mg/m 2/d for 5 days repeated every 3 weeks. Pharmacokinetic studies and UGT1A1 genotyping were performed. Results: Of 161 patients assessable for response, one patient with hepatoblastoma had a complete response, with partial responses observed in patients with medulloblastoma (n = 4), rhabdomyosarcoma (n = 1), neuroblastoma (n = 1), and germinoma (n = 1), for an overall response rate of 5%. Grade 4 neutropenia and grade 3 to 4 diarrhea occurred in less than 7% of the courses administered. Pharmacokinetic studies were available for 79 patients. The mean ± standard deviation IRN plasma clearance was 374 ± 148 mL/min/m 2, with median relative extent of conversion and relative extent of glucuronidation of 0.05 (range, 0.01 to 0.25) and 2.24 (range, 0.39 to 9.6), respectively. No association between UGT1A1 genotype (n = 61) and toxicity or pharmacokinetic parameters was observed. Conclusion: IRN 50 mg/m 2/d for 5 days every 21 days is well tolerated, but was not effective as a single agent in a spectrum of solid tumors, with the possible exception of patients with medulloblastoma (16% response rate). There was no association between UGT1A1*28 genotype and toxicity or pharmacokinetic parameters.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.11.6103

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 141

Metadata

Authors
Bomgaars, L. R., Bernstein, M., Krailo, M., Kadota, R., Das, S., Chen, Z., Adamson, P. C., & Blaney, S. M.
Venue
Journal of Clinical Oncology
Published
2007-10-10
Volume
25
Issue
29
Pages
4622-4627
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2147684739
Cited by
141
References
1
FWCI
4.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study. https://app.cochat.ai/papers/10.1200/jco.2007.11.6103
The paper
Bomgaars, L. R., Bernstein, M., Krailo, M., Kadota, R., Das, S., Chen, Z., Adamson, P. C., & Blaney, S. M. (2007). Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.11.6103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.